PediAid
PediAid
loading academics…

Expectant Management or Early Ibuprofen for Patent Ductus Arteriosus

BENEDUCTUS Trial · NEJM · 2022

The BENEDUCTUS trial was a multicentre, randomized, noninferiority trial involving 273 extremely preterm infants (<28 weeks' gestation) with echocardiographically confirmed PDA. It compared expectant management with early ibuprofen treatment initiated within 72 hours of birth. Expectant management was noninferior to early ibuprofen for the primary composite outcome of necrotizing enterocolitis (NEC), moderate-to-severe bronchopulmonary dysplasia (BPD), or death at 36 weeks' postmenstrual age (46.3% vs 63.5%). Early ibuprofen did not improve major neonatal outcomes despite promoting ductal closure. The findings support expectant management as an appropriate initial strategy in selected extremely preterm infants with PDA.

What It Found

The primary composite outcome of NEC, moderate-to-severe BPD, or death occurred in 46.3% (expectant management group) vs 63.5% (ibuprofen group), demonstrating noninferiority.

Moderate-to-severe BPD occurred in 33.3% (expectant management group) vs 50.9% (ibuprofen group).

NEC occurred in 17.6% (expectant management group) vs 15.3% (ibuprofen group).

Death occurred in 14.0% (expectant management group) vs 18.2% (ibuprofen group).

Early ibuprofen promoted ductal closure but did not improve major clinical outcomes.

The findings challenged routine early pharmacological PDA closure in extremely preterm infants.

Open-label design introduced potential treatment and assessment bias.

Sample size was relatively small (273 infants).

Results may not apply to hemodynamically unstable infants requiring urgent PDA intervention.

Long-term neurodevelopmental outcomes were not assessed in the primary report.

The study was not designed to establish the optimal treatment strategy for persistent symptomatic PDA.

Findings are primarily applicable to infants <28 weeks' gestation

Expectant management is noninferior to early ibuprofen for major neonatal outcomes.

Routine early PDA closure does not necessarily improve survival or reduce BPD.

Echocardiographic PDA closure should not be considered a surrogate for improved clinical outcomes.

Conservative management is a reasonable initial approach in clinically stable extremely preterm infants.

PDA treatment decisions should be individualized according to clinical condition and hemodynamic significance.